financetom
Business
financetom
/
Business
/
Apple wins $250 US jury verdict in patent case over Masimo smartwatches
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Apple wins $250 US jury verdict in patent case over Masimo smartwatches
Nov 3, 2024 12:19 PM

(Reuters) -Apple convinced a federal jury on Friday that early versions of health monitoring tech company Masimo's smartwatches infringe two of its design patents as part of a broader intellectual property dispute between the companies.

The jury, in Delaware, agreed with Apple that previous iterations of Masimo's W1 and Freedom watches and chargers willfully violated Apple's patent rights in smartwatch designs.

But the jury awarded the tech giant, which is worth about $3.5 trillion, just $250 in damages - the statutory minimum for infringement in the United States.

Apple's attorneys told the court the "ultimate purpose" of its lawsuit was not money, but to win an injunction against sales of Masimo's smartwatches after an infringement ruling.

On that front, jury also determined that Masimo's current watches did not infringe Apple patents covering inventions that the tech giant had accused Masimo of copying.

Masimo said in a statement it appreciated the jury's verdict "in favor of Masimo and against Apple on nearly all issues," and that the decision only applied to a "discontinued module and charger."

"Apple primarily sought an injunction against Masimo's current products, and the jury's verdict is a victory for Masimo on that issue," Masimo said.

Apple said in a statement that it was "glad the jury's decision today will protect the innovations we advance on behalf of our customers."

Irvine, California-based Masimo accused Apple of hiring away its employees and stealing its pulse oximetry technology after discussing a potential collaboration.

Masimo convinced the U.S. International Trade Commission last year to block imports of Apple's Series 9 and Ultra 2 smartwatches after the commission found their technology for reading blood oxygen levels infringed Masimo's patents.

Apple has appealed the decision and resumed selling the watches after removing the technology. The tech giant countersued Masimo for patent infringement in 2022, alleging Masimo copied Apple Watch features to use in its smartwatches.

Apple also accused Masimo of using lawsuits at the ITC and in California to "make way for Masimo's own watch."

Masimo said Apple's patent lawsuit was "retaliatory" and "an attempt to avoid the court in which the parties have been litigating their dispute."

(Reporting by Blake Brittain in Washington; Editing by Leslie Adler, Rosalba O'Brien and Lincoln Feast.)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
American Lithium's Fiscal Q3 Loss Narrows
American Lithium's Fiscal Q3 Loss Narrows
Jan 15, 2025
05:25 PM EST, 01/15/2025 (MT Newswires) -- American Lithium ( AMLIF ) after close of trade Wednesday its fiscal third-quarter loss narrowed. The lithium explorer said it lost $3.64-million, or $0.02 per share, in the quarter ended Nov.30, compared with a loss of $11.17 million, or $0.05, in the year-prior period. It ended the quarter with $3.49 million of cash...
Cellectis Files for Resale of 44 Million Company Shares by AstraZeneca
Cellectis Files for Resale of 44 Million Company Shares by AstraZeneca
Jan 15, 2025
05:26 PM EST, 01/15/2025 (MT Newswires) -- Cellectis ( CLLS ) filed a registration statement with the US Securities and Exchange Commission on Wednesday for the potential resale of up to 44 million ordinary shares, including in the form of American Depository Shares, by AstraZeneca Holdings from time to time. Cellectis ( CLLS ) said it will not receive any...
Silexion Shares Rise Late Following Pretrial Data From Pancreatic Cancer Treatment Showing Efficacy
Silexion Shares Rise Late Following Pretrial Data From Pancreatic Cancer Treatment Showing Efficacy
Jan 15, 2025
05:23 PM EST, 01/15/2025 (MT Newswires) -- Silexion Therapeutics ( SLXN ) was 74% higher in Wednesday's after-hours session, after it disclosed preclinical data demonstrated the synergistic efficacy of its SIL-204 candidate to treat certain form of pancreatic cancer. The data show that SIL-204 worked well in combination with the primary components of two chemotherapies, 5-fluorouracil and irinotecan, in human...
Alphabet CEO to join tech leaders at Trump inauguration
Alphabet CEO to join tech leaders at Trump inauguration
Jan 15, 2025
(Reuters) - Alphabet CEO Sundar Pichai is among the Big Tech leaders planning to attend U.S. President-elect Donald Trump's inauguration on Monday, a person familiar with the matter told Reuters on Wednesday. Apple's ( AAPL ) Tim Cook will also be attending the event, Bloomberg News reported earlier in the day. Tech CEOs Elon Musk, Jeff Bezos and Mark Zuckerberg...
Copyright 2023-2026 - www.financetom.com All Rights Reserved